Over Cabrera
Over Cabrera has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Jianxin Yang
Pfizer Global Research and Development, Groton, CT, USA
1 shared publication - John D Baker
Current Address: Neurosciences at Johnson & Johnson PRD, USA
1 shared publication - Judith L Treadway
Pfizer Global Research and Development, Groton, CT, USA
1 shared publication - Li Xi
Pfizer Inc., Portland St., Cambridge, MA 02139, USA
1 shared publication - Margit L MacDougall
Pfizer Global Research and Development, Groton, CT, USA
1 shared publication - Mark P. Molloy
Bowel Cancer and Biomarker Research Laboratory, Faculty of Medicine and Health, School of Medical Sciences, The University of Sydney, Sydney, NSW 2006, Australia
1 shared publication
Latest Publications
- Open Access
- 1 June 2011
- Published by Springer Nature in BMC Genomics
- Vol. 12 (1) , 281
Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
Glucagon is an important hormone in the regulation of glucose homeostasis, particularly in the maintenance of euglycemia and prevention of hypoglycemia. In type 2 Diabetes Mellitus (T2DM), glucagon levels are elevated in both the fasted and postprandial states, which contributes to inappropriate hyperglycemia through excessive hepatic glucose production. Efforts to discover and evaluate glucagon receptor antagonists for the treatment of T2DM have been ongoing for approximately two decades, with the challenge being to identify an agent with appropriate pharmaceutical properties and efficacy relative to potential side effects. We sought to determine the hepatic & systemic consequence of full glucagon receptor antagonism through the study of the glucagon receptor knock-out mouse (Gcgr-/-) compared to wild-type littermates.
- 1 June 2011
- Published by Springer Nature in BMC Genomics
- Vol. 12 (1) , 281
Open AccessPolyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes
Glucagon is an important hormone in the regulation of glucose homeostasis, particularly in the maintenance of euglycemia and prevention of hypoglycemia. In type 2 Diabetes Mellitus (T2DM), glucagon levels are elevated in both the fasted and postprandial states, which contributes to inappropriate hyperglycemia through excessive hepatic glucose production. Efforts to discover and evaluate glucagon receptor antagonists for the treatment of T2DM have been ongoing for approximately two decades, with the challenge being to identify an agent with appropriate pharmaceutical properties and efficacy relative to potential side effects. We sought to determine the hepatic & systemic consequence of full glucagon receptor antagonism through the study of the glucagon receptor knock-out mouse (Gcgr-/-) compared to wild-type littermates.